Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4223975 | 1.00 | OPRM1 (0.65) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL8055493 | 1.00 | OPRM1 (0.65) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| Maleic Acid SCHEMBL6116431 | 0.95 | KMT2A (0.68) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL25675486 | 0.91 | OPRM1 (0.56) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL3193334 | 0.89 | OPRM1 (0.54) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL14350787 | 0.87 | OPRM1 (0.55) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL4234741 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL10300834 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL10300830 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1NR1I2CHRM2ADORA3 | |
| SCHEMBL4234492 | 0.84 | OPRM1 (0.58) | OPRM1OPRD1NR1I2CHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| WO-2018029545-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| EP-2024323-B1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | GICARE PHARMA INC (CA) | 2013-03-27 | — | — | EP | disclosed |
| US-7666907-B2 | Salts of trimebutine and N-desmethyl trimebutine | ANTIBE THERAPEUTICS INC. (CA) | 2010-02-23 | — | — | US | disclosed |
| US-7666907-B2 | Salts of trimebutine and N-desmethyl trimebutine | ANTIBE THERAPEUTICS INC. (CA) | 2010-02-23 | — | — | US | disclosed |
| CN-101489986-A | Salts of trimebutine and N-desmethyl trimebutine | ANTIBE THERAPEUTICS INC (CA) | 2009-07-22 | — | — | CN | disclosed |
| EP-2024323-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | Antibe Therapeutics Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007140611-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140611-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-12-13 | — | — | WO | disclosed |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-11-29 | — | — | US | disclosed |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-11-29 | — | — | US | disclosed |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | OPRM1 498/4885OPRD1 290/4885NR1I2 134/4885 |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | SI, VIP, TRIM59 | OPRM1 389/4885OPRD1 169/4885NR1I2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.